Abstract
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have